Search Results
Jan 06, 2026, 09:30 ET Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
/PRNewswire/ -- The Lung Cancer Research Foundation® (LCRF) recently awarded five new research grants in the following areas: three LCRF Leading-Edge Research Awards, one LCRF Research Grant on Overcoming Resistance in Lung Cancer Award, and one LCRF Minority Career Development Award (CDA) for Lung Cancer. These
More news about: Lung Cancer Research Foundation
Jan 06, 2026, 09:00 ET BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
drug-resistant lung cancer. Launched by the National Cancer Center Hospital East (Kashiwa, Japan; "NCCHE") in 2020 with over 100 institutions as part of its network, the study analyzed approximately 2,000 clinical specimens from patients with advanced or recurrent non-small cell lung cancer (NSCLC) following
More news about: BillionToOne
Jan 06, 2026, 08:53 ET NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
clinical programs have advanced LSAM investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. Feasibility of the PurcisionTM platform has been established in taxanes, platins, tyrosine
More news about: NanOlogy LLC
Jan 06, 2026, 07:00 ET Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
Jan 05, 2026, 12:27 ET Oklahoma Proton Center Featured In Award-Winning Documentary Film
wide range of cancers. Oklahoma Proton Center treats hundreds of patients a year from around the country for a variety of cancers including breast, lung, prostate, brain, esophageal, head and neck, and more.To learn more about the Oklahoma Proton Center, visit
More news about: Oklahoma Proton Center
Jan 05, 2026, 09:00 ET Function Launches "Eat Different" to Challenge a Food System Built for Convenience, Not Health
accessible to more people. The advanced MRI can detect cancers, unruptured aneurysms, endometriosis, signs of stroke, etc., while the CT scan can identify lung cancer, plaque in the heart, etc. All data is integrated into a single intelligent interface, giving each member a personalized view of their health
More news about: Function Health
Jan 05, 2026, 08:05 ET Accord BioPharma's HERCESSI™ (trastuzumab-strf) Gains Preferred Status on Express Scripts National Commercial Formularies
respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactionsPatients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicityExacerbation
More news about: Accord BioPharma
Jan 05, 2026, 04:30 ET 第六項BTD！蘆康沙妥珠單抗(sac-TMT)聯合免疫療法K藥一線治療PD-L1陽性NSCLC獲突破性療法認定
請。此前，公司公布了蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療PD-L1陽性NSCLC的III期OptiTROP-Lung05臨床試驗結果，其在主要終點無進展生存期(PFS)顯示出統計學意義和臨床意義的顯著改善，並在總生存期(OS)方面觀察到獲益趨勢。OptiTROP-Lung05研究是首個免疫聯合ADC在一線治療NSCLC上達到主要終點的III期臨床研究。此次在一線治療PD-L1陽性NSCLC獲得突破性療法認定，將為加速蘆康沙妥珠單抗(sac-TMT)在此適應症審評與上市進程提供助力。截至目前，蘆康沙妥珠單抗(sac-TMT)先後已獲得五項突破性療法認定，分別用於：
More news about: 科倫博泰
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and ALK-negative.
More news about: Kelun-Biotech
Jan 05, 2026, 04:03 ET Invisible Danger: Lung Association Urges Home Testing for Cancer-Causing Radon Gas
Lung.org/radon-basics.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Jan 02, 2026, 07:00 ET Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Dec 30, 2025, 16:05 ET TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P. Morgan Healthcare
More news about: TransMedics Group, Inc.
Dec 29, 2025, 11:11 ET Arkansas Children's Receives Historic $50 Million Gift from Philanthropist B. Thomas Golisano
pediatric subspecialties (2025-2026): Cancer, Cardiology & Heart Surgery, Nephrology, Neurology & Neurosurgery, Orthopedics, Pulmonology & Lung Surgery and Urology. ACNW, the first and only pediatric hospital in the northwest Arkansas region, is a Level IV pediatric trauma center. ACNW operates
More news about: Arkansas Children’s
Dec 26, 2025, 11:02 ET CGTN: Proč čínská protikorupční kampaň nikdy nekončí
k dosažení hmatatelných výsledků, které pocítí veřejnost.Hmatatelné výsledky podtrhují tento závazek. V severovýchodní čínské provincii Chej-lung-ťiang odhalil model dohledu založený na datech zneužití dotací na odborné vzdělávání. V jihozápadním čínském městě Čchung-čching nyní posílený dohled
More news about: CGTN
Dec 26, 2025, 10:46 ET CGTN: Prečo čínske úsilie o boj proti korupcii nikdy nekončí
životy ľudí, a na dosiahnutie hmatateľných výsledkov, ktoré verejnosť pocíti.Hmatateľné výsledky tento záväzok podčiarkujú. V provincii Chej-lung-ťiang v severovýchodnej Číne odhalil model dohľadu založený na údajoch o spreneverení dotácií na odborné vzdelávanie. V juhozápadnej Číne v obci Čchung-čching
More news about: CGTN
Dec 26, 2025, 10:00 ET Dreame Technology Spreads Holiday Cheer with Donation of 60 Air Purifiers to Save the Children
Studies cited from the American Lung Association have shown that children are 2-5 times more likely to suffer from asthma and other respiratory diseases in environments with poor air
More news about: Dreame Technology
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations;For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who progressed after EGFR-TKI therapy;For the first-line
More news about: Innovent Biologics
Dec 24, 2025, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 6,333
More news about: TransMedics Group, Inc.
Dec 24, 2025, 08:04 ET Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
Dec 23, 2025, 18:37 ET SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.
in December 2024 for the treatment of small cell lung cancer. Subsequently, a regulatory protocol review is currently underway in Europe for phase 2 trials, which will evaluate both monotherapy and combination therapy in patients with small cell lung cancer.
More news about: SN BioScience Inc.
Dec 23, 2025, 10:18 ET INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Dec 23, 2025, 06:55 ET Gundry MD Bio Complete 3 Reviews: 2,400+ Positive Reviews, Users Rave About Improved Digestion, Energy & Gut Health Support
Gundry MD, Dr. Steven Gundry was one of the world's top cardiothoracic surgeons. Currently, he's the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Santa Barbara, California, where he's spent the past 25 years helping people
More news about: Gundry MD
Dec 22, 2025, 11:24 ET First IPF Biomarker Clears Initial FDA Step Toward Qualification
need in IPF drug developmentIPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial lung diseases (ILDs), and researchers are working urgently to bring
More news about: The Pulmonary Fibrosis Foundation
Dec 22, 2025, 08:46 ET Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
(ARDS). Upon the next round of funding, the company will initiate the multicenter PAISANO trial – Preventing the Advance of Lung Fibrosis via the ALT-100 Antibody – to investigate the safety, pharmacokinetics, pharmacodynamic, and efficacy of
More news about: Aqualung Therapeutics
Dec 22, 2025, 07:00 ET U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000 people in the U.S. and up to 5.6 million worldwide, PPF is linked to an underlying clinical interstitial lung disease (ILD) diagnosis, such
More news about: Boehringer Ingelheim